You are here

Share:

Search Technologies

Showing 81-100 of 132 results found

Anti-Glypican 2 Chimeric Antigen Receptor (CAR) Containing CD28 Hinge And Transmembrane Domains For Treating Neuroblastoma

Chimeric antigen receptor (CAR) T cells that specifically target Glypican 2 (GPC2) are strong therapeutic candidates for patients with neuroblastoma and other GPC2-expressing cancers. The inventors at the National Cancer Institute (NCI) have developed a potent anti-GPC2 (CT3) CAR containing CD28 hinge and transmembrane domains (CT3.28H.BBζ) that is available for licensing and co-development.

High Affinity Monoclonal Antibodies Targeting Glypican-1

Researchers at the National Cancer Institute (NCI) have isolated two Glypican-1- (GPC1)- specific antibodies: the mouse monoclonal antibody HM2 that binds the C-lobe of GPC1 close to the cell surface, and the camel single domain antibody D4. The D4 single domain antibody (also called ‘nanobody’) has a high affinity for GPC1-positive tumor cells from both human and mouse origins. The NCI seeks licensing and/or co-development research collaborations to advance the development and commercialization of these antibodies.

High Affinity Cross Species Single Domain Antibodies Targeting Mesothelin

Researchers at the National Cancer Institute (NCI) have isolated two high affinity anti-mesothelin single domain antibodies (also known as nanobodies), A101 and G8. These antibodies have been isolated from NCI’s newly developed camel single domain (VHH) libraries by phage display. The antibodies have a high affinity for mesothelin-positive tumor cells from both human and mouse origins. The NCI seeks licensing and/or co-development research collaborations to advance the development and commercialization of these antibodies.

Use of Acetalax for Treatment of Triple Negative Breast Cancer

The National Cancer Institute (NCI) seeks research co-development and/or potential licensees for a potential novel treatment for triple-negative breast cancer (TNBC) with acetalax (oxyphenisatin acetate). Acetalax is a previously FDA approved drug that has been used as a topical laxative but is being repurposed here as an onco-therapy because of its cytotoxic effects on a number of TNBC and other cancer cell lines.

Multi-epitope Vaccines against TARP (ME-TARP) for Treating Prostate and Breast Cancer

Researchers at the NCI have developed a treatment for prostate and breast cancer using multivalent peptides derived from TARP, the T cell receptor gamma alternate reading frame protein. These immunogenic peptides from TARP elicit an immune response, triggering T cells to kill only the cancer cells within a patient. NCI seeks licensees or co-development partners to commercialize this invention.

Analogues of Withanolide E Sensitize Cancer Cells Toward Apoptosis

There is a need to develop compounds that can sensitize cancer cells to apoptosis inducing ligands, such as poly I:C and TRAIL. In collaboration with the University of Arizona, NCI investigators discovered a series of compounds in the withanolide family that synergistically enhance the response of cancer cells to treatment with an apoptosis-inducing ligand. The NCI seeks licensing and/or co-development research collaborations for development of withanolide E analogues for the treatment of cancer.

Use of Cucurbitacins and Withanolides for the Treatment of Cancer

The National Cancer Institute's Laboratory of Experimental Immunology, Cancer Inflammation Program, seeks parties interested in collaborative research to co-develop, evaluate, or commercialize the use of certain cucurbatacins or withanolides in combination with pro-apoptotic agonists of TRAIL death receptors for cancer therapy.

Cancer Immunotherapy Using Virus-like Particles

A considerable effort has been devoted to identifying and targeting specific extracellular cancer markers using antibody based therapies. However, diminished access to new cancer cell surface markers has limited the development of corresponding antibodies. NCI Technology Transfer Center is seeking to license cancer immunotherapy using virus-like particles.

Brachyury-directed Vaccine for the Prevention or Treatment of Cancers

Researchers at the NCI have developed a vaccine technology that stimulates the immune system to selectively destroy metastasizing cells. Stimulation of T cells with the Brachyury peptide promote a robust immune response and lead to targeted lysis of invasive tumor cells. NCI seeks licensing or co-development of this invention.

Genetically Modified Hematopoietic Stem And Progenitor Cells (HSPCs) And Mesenchymal Cells As A Platform To Reduce Or Prevent Metastasis, Treat Autoimmune And Inflammatory Disorders, And Rebalance The Immune Milieu And Dysregulated Niches

There is a marked increase in immunosuppressive myeloid progenitors and myeloid cells in tumors and at metastatic tissue sites, rendering these types of cells useful in cancer therapeutics – especially after genetic modifications to improve their anti-tumor properties. The National Cancer Institute (NCI) seeks research co-development or licensing for genetically engineered myeloid cells (GEMys) for use in cancer immunotherapy.

In silico design of RNA nanoparticles

The National Cancer Institute seeks parties interested in licensing or collaborative research to co-develop RNA nanostructures using computational and synthetic methods.

Improved HIV Vaccines Through Ras Activation

The National Cancer Institute (NCI) Vaccine Branch, seeks research co-development or licenses for a novel method of improving HIV vaccine efficacy by activating Ras signaling. Upregulating the Ras pathway can improve an HIV patient’s immune response to anti-retroviral vaccines.

Pages